Upgrade to SI Premium - Free Trial

Form 4 Global Medical REIT Inc. For: Mar 05 Filed by: KIERNAN ROBERT J

March 7, 2018 8:11 PM
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: December 31, 2014
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person *
KIERNAN ROBERT J

(Last) (First) (Middle)
2 BETHESDA METRO CENTER, SUITE 440

(Street)
BETHESDA MD 20814

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Global Medical REIT Inc. [ GMRE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Financial Officer
3. Date of Earliest Transaction (Month/Day/Year)
03/05/2018
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
LTIP Unit (Right to Buy) (1) (2) 03/05/2018 (3) A 2,225 (3) (2) (2) Common Stock 2,225 $ 0 8,199 D
LTIP Unit (Right to Buy) (4) (2) 03/05/2018 (4) A 19,727 (4) (2) (2) Common Stock 19,727 $ 0 27,926 D
LTIP Unit (Right to Buy) (5) (2) 03/05/2018 (5) A 9,469 (5) (2) (2) Common Stock 9,469 $ 0 37,395 D
Explanation of Responses:
1. Represents units of limited partnership interest ("LTIP Units") in Global Medical REIT L.P. (the "OP"), the operating partnership of the Issuer. The Issuer's Board of Directors determined on March 5, 2018 that 50% of the LTIP Units vested and became nonforfeitable as a result of meeting certain market based performance criteria as of December 31, 2017 and 50% of the LTIP Units will vest on December 31, 2018, pursuant to the grant award agreement stipulations. The performance-based LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
2. As described in the OP's partnership agreement, vested LTIP Units may be exchanged at any time after vesting for cash or, at the election of the Issuer, for shares of Common Stock on a one-for-one basis. LTIP Units have no expiration date.
3. Awarded pursuant to an LTIP Unit performance-based vesting agreement, the form of which was filed as Exhibit 99.2 to the Issuer's Current Report on Form 8-K filed on March 6, 2017.
4. Represents LTIP Units in the OP granted as a retention award. The Issuer's Board of Directors determined on March 5, 2018 that 50% of the LTIP Units will vest on March 5, 2020 and 50% of the LTIP Units will vest on March 5, 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
5. LTIP Units vest in equal one-third installments on March 5 of 2019, 2020 and 2021. The LTIP Units were issued pursuant to the Issuer's 2016 Equity Incentive Plan and have no expiration date.
/s/ Robert Kiernan 03/07/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Categories

SEC Filings